0001104659-22-106784.txt : 20221006 0001104659-22-106784.hdr.sgml : 20221006 20221006162122 ACCESSION NUMBER: 0001104659-22-106784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221006 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221006 DATE AS OF CHANGE: 20221006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 221298408 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 8-K 1 tm2227731d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2022

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38129

04-3562403

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

840 Memorial Drive Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (617) 498-0020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	MRSN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On October 6, 2022, Mersana Therapeutics, Inc. (the “Company”) posted an updated corporate presentation on the Company’s website. To access the presentation, investors should visit the “Events & Presentations” page under the “Investors & Media” section of the Company’s website at ir.mersana.com.

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company with the Securities and Exchange Commission under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 8.01

Other Events.

On October 6, 2022, the Company issued a press release announcing the completion of patient enrollment in UPLIFT, the Company’s single-arm registrational trial evaluating the safety and efficacy of upifitamab rilsodotin in patients with platinum-resistant ovarian cancer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by the Company on October 6, 2022.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERSANA THERAPEUTICS, INC.

Date: October 6, 2022	By:	/s/ Brian DeSchuytner
		Brian DeSchuytner
		Senior Vice President, Chief Financial Officer

EX-99.1 2 tm2227731d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a

Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

-

Topline data from UPLIFT expected in mid-2023

-

Targeting potential Biologics License Application (BLA) submission by the end of 2023

CAMBRIDGE, Mass., October 6, 2022 – Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the completion of patient enrollment in UPLIFT, the company’s single-arm registrational trial of UpRi in platinum-resistant ovarian cancer. UpRi is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables a high drug-to-antibody ratio and controlled bystander effect.

“The completion of enrollment in UPLIFT moves us one step closer to our goal of establishing UpRi as a foundational therapy for ovarian cancer,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “Thanks in large part to the enthusiasm we have seen about UpRi among global investigators, the significant unmet needs of patients in the platinum-resistant setting and strong execution from our team, we were able to enroll more than 270 patients in this trial within approximately a year. As a result, we believe we will have a robust data set for a planned topline data readout from UPLIFT in mid-2023 and, assuming positive data, a potential U.S. Food and Drug Administration BLA submission by the end of 2023. We extend our sincere thanks to the patients, caregivers, clinical investigators and staff who are participating in UPLIFT.”

UPLIFT is a single-arm clinical trial evaluating the safety and efficacy of UpRi in patients with platinum-resistant ovarian cancer who have received up to four prior lines of therapy. Patients with three or four prior lines of therapy were able to enroll in UPLIFT without regard to prior bevacizumab treatment. The trial enrolled a total of 272 patients to receive a 36 mg/m² dose of UpRi every four weeks. While NaPi2b testing of patient tumor samples is ongoing, the company expects that it will exceed its targeted number of NaPi2b positive patients in UPLIFT. The trial’s primary endpoint is the objective response rate (ORR) in the NaPi2b positive population, and secondary endpoints include the ORR regardless of NaPi2b expression, as well as duration of objective response and incidence and severity of adverse events.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors and Media” section of its website at www.mersana.com.

Forward-Looking Statements

This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, those concerning the therapeutic potential of Mersana’s product candidates, including UpRi’s potential to serve as a foundational therapy in ovarian cancer, the objectives of the UPLIFT clinical trial, Mersana’s expectations regarding the number of NaPi2b positive patients determined to be enrolled following completion of screening, the timing of top-line data from the trial, the possibility that top-line data from UPLIFT and other available data will support a BLA submission and the possible timing of any such BLA submission. Mersana may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including, among other things, uncertainties inherent in research and development, in the conduct of clinical trials and in the clinical development of Mersana’s product candidates; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the risk that the NaPi2b positive prevalence in patients enrolled in the UPLIFT trial is different than that shown in prior studies of ovarian cancer patients; potential adverse effects arising from the use of UpRi or other product candidates; the risk that Mersana may not realize the intended benefits of its platforms, technology and collaborations; risks to patient follow-up, as well as to Mersana’s abilities to meet other anticipated deadlines and milestones, whether presented by the ongoing COVID-19 pandemic or otherwise; the risk that data from the UPLIFT trial may not support the submission of a BLA; risks related to the regulatory approval process and other important factors, any of which could cause Mersana’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the section entitled “Risk Factors” in Mersana’s Annual Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2022, as well as in other filings Mersana may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mersana expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Contact:

Jason Fredette

617-498-0020

jason.fredette@mersana.com

EX-101.SCH 3 mrsn-20221006.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrsn-20221006_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mrsn-20221006_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 06, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 06, 2022
Entity File Number	001-38129
Entity Registrant Name	MERSANA THERAPEUTICS, INC.
Entity Central Index Key	0001442836
Entity Tax Identification Number	04-3562403
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	840 Memorial Drive
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	617
Local Phone Number	498-0020
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	MRSN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2227731d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001442836 2022-10-06 2022-10-06 iso4217:USD shares iso4217:USD shares 0001442836 false 8-K 2022-10-06 MERSANA THERAPEUTICS, INC. DE 001-38129 04-3562403 840 Memorial Drive Cambridge MA 02139 617 498-0020 false false false false Common Stock, $0.0001 par value MRSN NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mersana.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2227731d1_8k.htm mrsn-20221006.xsd mrsn-20221006_lab.xml mrsn-20221006_pre.xml tm2227731d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2227731d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2227731d1_8k.htm" ] }, "labelLink": { "local": [ "mrsn-20221006_lab.xml" ] }, "presentationLink": { "local": [ "mrsn-20221006_pre.xml" ] }, "schema": { "local": [ "mrsn-20221006.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrsn", "nsuri": "http://mersana.com/20221006", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2227731d1_8k.htm", "contextRef": "From2022-10-06to2022-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://mersana.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2227731d1_8k.htm", "contextRef": "From2022-10-06to2022-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-106784-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-106784-xbrl.zip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end